tau silencing gene therapy program (Voyager Therapeutics)

N/A

Report date: 2025/06/11 10:32:10

Base Information

Drug Nametau silencing gene therapy program (Voyager Therapeutics)

Drug Alias NameC9P39.TAU-2023

ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vectorSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA

Mechanisms of ActionMicrotubule-associated protein tau inhibitorsNeuroprotectants

TargetsMicrotubule-associated protein tau

Therapy Area/IndicationsAlzheimer Disease

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesVoyager Therapeutics Inc

China Registration ClassN/A

Develop Information

Active CompaniesVoyager Therapeutics Inc

Inactive CompaniesN/A

Active IndicationsAlzheimer Disease

Inactive IndicationsN/A

Other Information

ATC CodeN/A